Galapagos ( ($GLPG) ) just unveiled an update. On November 3, 2025, Galapagos NV announced that it will present new data for its CAR T-cell ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...

A new study led by Swansea University has revealed a new way to potentially treat certain autoimmune diseases by targeting a ...

G-Rex based manufacturing process to produce gene-modified regulatory T cell (Treg) therapies for autoimmune disorders ...

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T ...